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Abstract: Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, 
including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor 
receptor (EGFR). The activity against RET and VEGF made it a good choice in the treatment of medullary thyroid cancer (MTC). 
As there is considerable cross talk between growth factor pathways, dual inhibition with such agents has become an attractive strategy, in 
the treatment of many malignancies with encouraging Phase II clinical trial data to date. Vandetanib was tested in two Phase II trials in 
the treatment of patients with medullary thyroid cancer at doses of 100 mg and 300 mg daily respectively. The encouraging results of these 
2 trials led to a randomized phase II trial comparing this medication to placebo using a crossover design. More than 300 patients were 
included in this study, which ultimately showed a significant improvement in progression-free survival in patients taking vandetanib. 
Based on these results, the Oncology Drug Advisory Committee (ODAC) of the Food and Drug Administration (FDA) recommended that 
vandetanib be approved for the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer.
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Introduction
Medullary thyroid cancer (MTC) accounts for fewer 
than 10% of all incident cases of thyroid malignancy 
but a disproportionately greater number (13.4%) of 
thyroid cancer-related deaths.1 Radioiodine is ineffec-
tive in the treatment of this indolent malignancy, which 
originates from the parafollicular C cells that produce 
calcitonin, and not iodine-rich thyroid hormone. The 
pathogenesis of this disease has been extensively doc-
umented over the past 50 years. Soon after the earliest 
descriptions  of  this  disease  in  1959,2  there  were 
reports of a familial syndrome, initially in a single 
family3 and subsequently associated with other disor-
ders  including  pheochromocytomas  and  primary 
hyperparathyroidism.4,5 It is now clear that there are 
multiple  hereditary  forms  of  this  cancer,  including 
familial MTC (FMTC) and the Multiple Endocrine 
Neoplasia  Syndromes  (MEN  2A  and  MEN  2B), 
although the sporadic form still constitutes the major-
ity of the cases.6 MEN 2A accounts for 60% of the 
hereditary forms, MEN 2B 5%, and FMTC 35%.7
Distant  metastatic  disease  is  the  main  cause  of 
death in patients with MTC, occurring at presentation 
in  approximately  half  of  incident  cases  and  often 
involving multiple organs such as the liver, lungs, and 
bones.8  Extra-cervical  metastases  and  unresectable 
advanced  local  disease  are  essentially  incurable. 
Consequently, the best chance of curing patients with 
the disease is to identify patients at an early stage 
when the tumor is amenable to resection, especially if 
it  is  confined  to  the  thyroid.  In  a  review  of  over 
1200 cases, the mean survival time after the diagnosis 
of MTC was 8.6 years (range, 0–29.6 years). Patients 
with  tumors  confined  to  the  thyroid  gland  had  a 
10-year survival rate of 95.6%, whereas patients with 
regional stage disease had an overall survival rate of 
75.5%. Patients with distant metastases at diagnosis 
had  a  poor  prognosis,  with  only  40%  surviving 
10  years.9  Although  traditional  cytotoxic  chemo-
therapy and radiation techniques have been histori-
cally  ineffective  in  MTC,  novel  small  molecule 
tyrosine kinase inhibitors appear to hold promise.10
Targeted Therapy
The explosion of targeted therapies in the field of 
medical oncology has given the potential for effec-
tive treatments for previously incurable diseases such 
as chronic myeloid leukemia.11 A hallmark of MTC 
is  the  association  with  the  rearranged  during 
  transfection proto-oncogene (RET) which as noted 
above, is involved in cell signalling, and regulation 
of the production of proteins that are essential for 
spermatogenesis and the development of the auto-
nomic  nervous  system  and  kidneys.  Mutations  in 
specific regions of the RET gene have been described 
in MTC, and these occur in both the sporadic and 
familial  forms  of  the  disease.12,13 These  mutations 
have  motivated  experiments  looking  at  corrective 
gene therapy as a treatment strategy.14
ReT (Rearranged During Transfection) 
proto-Oncogene
Until recently, it was likely that the detection of tumor 
at an early stage occurred either by the incidental 
finding of a thyroid nodule, or through screening of 
family members of an index patient who had previ-
ously  been  diagnosed  with  MTC  or  with  the 
MEN 2 syndrome. Previous work had shown that the 
MEN syndromes are inherited in an autosomal domi-
nant manner,15 suggesting that 50% of patients would 
be screened unnecessarily. The yield from screening 
was improved with the discovery in 1985 of a new 
human transforming gene detected by transfection of 
NIH 3T3 cells with a lymphoma DNA.16 Subsequent 
work pinpointed mutations on chromosome 10, fol-
lowed by the identification of germline mutations in 
the  RET  (rearranged  during  transfection)  proto- 
oncogene,  located  at  10q11.2,  in  patients  with 
MEN 2A, MEN 2B, and FMTC.6
Receptor tyrosine kinases (RTK) including RET, 
receive the extracellular signals for processes as 
diverse  as  cell  growth,  differentiation,  survival, 
and programmed cell death (Fig. 1). In response to 
binding  of  extracellular  ligands,  RTKs  generally 
form homodimers or heterodimers. On dimeriza-
tion,  autophosphorylation  occurs,  followed  by 
intracellular signal transduction through effectors 
that recognize and interact with the phosphorylated 
form of the RTK. Although the downstream signal-
ing  pathways  activated  by  these  steps  may  be 
shared by different receptors, the ligand-receptor 
interaction itself is very specific. In some cases, 
however, high-affinity ligand-RTK interactions can 
be modulated by the presence of other, low-affinity, 
nonsignaling  accessory  molecules  at  the  cell 
surface.12vandetanib as a treatment for MTC
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Vascular endothelial Growth Factor 
Receptor (VeGFR) pathway
The VEGFR pathway is also important in the patho-
genesis  of  MTC.17 Three  transmembrane  receptors 
mediate the angiogenic and lymphogenic effects of 
VEGF;  VEGFR-1,  VEGFR-2  and  VEGFR-3.  Of 
these, VEGFR-2 is believed to play the primary role 
in endothelial cell proliferation, migration, survival 
and induction of vascular permeability characteristic 
of neo-vascularization required for tumor growth and 
metastasis. VEGF proteins secreted by the tumor cell 
act as ligands for the VEGFR receptors and a com-
plex feedback loop is involved in the stimulation of 
angiogenesis (Fig. 2).18
Vandetanib  (ZD6474,  ZactimaTM;  AstraZeneca) 
(N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-
methylpiperidin-4-yl)methoxy]  quinazolin-4-amine) 
ZD 6474 (Zactrima, Vandetanib) is an oral anilinqui-
nazoline compound with a molecular weight of 475 
Daltons. It competes with ATP binding in the cata-
lytic domain of several tyrosine kinases. Recombinant 
enzyme assays haves shown it to be a potent inhibitor 
of VEGFR-2 (50% inhibitory concentration [IC50] 
of 40 nM), with additional activity against   VEGFR-3 
(IC50  110  nM),  EGFR  (IC50  500  nM)  and  the 
  rearranged during transfection (RET; IC50130 nM) 
kinase.  Further  studies  on  human  umbilical  vein 
endothelial cells (HUVEC)  have found vandetanib 
to  potently  inhibit  proliferation  of  VEGFR  stimu-
lated cells (IC50 60 nM) with higher doses neces-
sary  for  EGFR  stimulated  HUVEC  proliferation 
(IC50 170 nM). Vandetanib showed excellent selec-
tivity for these kinases compared with related recep-
tor tyrosine kinases, such as platelet-derived growth 
factor receptor (PDGFR)-β and c-Kit.19–21 The   activity 
profile of this agent, made it an attractive choice as a 
treatment for patients with unresectable MTC.
Phase I studies
Two Phase I dose escalation studies evaluating daily 
vandetanib alone in advanced solid tumors have been 
completed.  The  first  was  conducted  in  the  United 
States and Australia, enrolling 77 patients, with colon 
cancer being the most common tumor type.22 Dose 
limiting  toxicities  included  diarrhea,  hypertension 
and rash. The recommended dose to evaluate in fur-
ther studies was 300 mg daily. This dose was toler-
ated well, with the most common toxicities being rash 
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Figure 1. Interaction of ligand with ReT and cell signaling pathways.
GDNF (Glial Cell Line-Derived Neutrotrophic factor), ReT/PTC (Rearranged during transfection/Papillary Thyroid Carcinoma), GFRα (GDNF Family 
Receptor α), PI3K (Phosphoinositide Kinase-3), FAK(Focal adhesion kinase-1), RAS (RAt Sarcoma), AKT (serine/threonine protein kinase), MAPK   
(mitogen-activated protein kinase), Shc (proteins containing Src homology 2 (SH2) domains). This diagram represents the ReT/PTC receptor. The ReT 
receptor is thought to involve similar downstream pathways.Deshpande et al
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and diarrhea. Asymptomatic QTc prolongation was 
also observed in 7 patients.   Pharmacokinetic studies 
showed vandetanib to be extensively distributed, with 
a half life of approximately 120 hours and a minimum 
of 28 days continuous oral dosing required to achieve 
steady-state  plasma  concentrations.  The  second 
Phase I study was conducted in Japan, and enrolled 
18 patients.23 Again, 300 mg daily was determined to 
be the recommended dose with similar toxicity   profile 
and pharmacokinetic findings.
studies Involving Vandetanib  
and MTc (Table 1)
Single arm phase II studies
Germline  mutations  of  RET  cause  the  hereditary 
forms of MTC, one of the main targets of Vandetanib. 
Therefore patients with unresectable, locally advanced 
or metastatic MTC with a confirmed clinical diagno-
sis of MEN2A, MEN2B or FMTC and a germline 
RET mutation were eligible for a study using this 
agent at an initial dose of 300 mg daily. Patients had 
to have at least one measurable lesion according to 
Response  Evaluation  Criteria  in  Solid  Tumors 
(RECIST) guidelines, WHO performance status of 
0–2 and adequate cardiac, hematopoietic, hepatic and 
renal function. This was an open-label, phase II study 
conducted at 7 centers. Patients received once-daily 
oral doses of Vandetanib 300 mg until disease pro-
gression, unacceptable toxicity, or withdrawal of con-
sent occurred. The primary endpoint was objective 
response by RECIST. Additional assessments included 
the duration of response, disease control, progression 
free survival (PFS) safety and tolerability and changes 
in the serum levels of polypeptide, calcitonin and the 
glycoprotein carcinoembryonic antigen (CEA) which 
are secreted by MTC cells. Between November 2004 
and August 2006, a total of 30 patients were enrolled. 
At the time of data cutoff (February 22 2008), seven-
teen patients were still continuing treatment. 4 had 
disease  progression  by  RECIST  measurements  but 
were receiving clinical benefits and allowed to remain 
on  study.  The  remaining  patients  discontinued 
  Vandetanib because of adverse events (n = 7) disease 
  progression (n = 4) or withdrawal of consent (n = 2). 
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Figure 2. Interaction of tumor cells with veGF proteins and the veGF receptors.
veGF (vascular endothelial growth factor), veGFR (vascular endothelial growth factor receptor), FAK(Focal adhesion kinase-1), RAS (RAt Sarcoma), 
AKT (serine/threonine protein kinase), MAPK (mitogen-activated protein kinase) Shc (proteins containing Src homology 2 (SH2) domains), PLC (Phos-
pholipase C), PKC (Protein Kinase C), NOS (Nitric Oxide Synthase).vandetanib as a treatment for MTC
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The majority of patients had MEN2A and 29 of the 30 
had evidence of metastatic disease at presentation. 
Twenty percent of subjects (6 patients) achieved a 
partial response, and another 53% had stable disease 
for  more  than  24  weeks.  The  median  duration  of 
response was 10.2 months (range 1.9–16.9 months; 
CI 8 to 13.2 months). The majority of patients (80%) 
had reductions in their calcitonin levels to less than 
half the baseline values for at least four weeks.24
The eligibility criteria was similar in a   second 
phase II study using a lower dose of the drug (100 mg) 
as monotherapy in patients with locally advanced 
or metastatic familial forms of MTC. The primary 
objective again was to assess the objective response 
rate with Vandetanib according to RECIST criteria. 
Upon disease progression however, all patients that 
the investigator believed may have been obtaining 
clinical benefit from therapy could enter postpro-
gression  treatment  with    Vandetanib  300  mg/day 
until objective disease progression occurred at this 
dose, or until another withdrawal criterion was met. 
19 patients were recruited between August 2006 and 
May 2007 all receiving 100 mg daily   initially. At the 
time of data cutoff 11 were continuing on this dose 
and the remaining had discontinued initial   treatment. 
Four of these had disease progression, and all entered 
postprogression treatment with   Vandetanib 300 mg 
daily. There were no complete responses, 3 (16%) 
partial responders and 10 patients had stable disease 
for 24 weeks or longer. In this study, disease control 
was seen in 68% of all patients (including complete 
and  partial  responders  and  those  who  had  stable 
disease for greater than 24 weeks.). Toxicities were 
manageable in both trials, with the most common 
adverse  events  being  diarrhea,  rash,  and  asymp-
tomatic  QTc  prolongation  on    electrocardiogram.25 
Although  it  could  be  seen  from  both  trials  that 
100 mg daily and 300 mg daily of Vandetanib each 
had activity in this disease, no direct   comparison 
of these dose levels has been conducted. The level 
  chosen for the randomized placebo controlled study 
was 300 mg daily.
The encouraging results of these single arm tri-
als spurred accrual onto an international randomized 
phase  II  trial  (known  as  the  ZETA  trial)  compar-
ing  ZD6474  to  placebo  in  patients  with  inherited 
and  sporadic  forms  of  MTC.26  In  this  large  trial, 
331  adults  with  unresectable  locally  advanced  or 
metastatic MTC were randomized in a 2:1 manner 
to receive either ZD6474 (Vandetanib) at a dose of 
300 mg daily, or placebo. Between December 2006 
and  November  2007,  231  subjects  were  assigned 
  Vandetanib and 100 received placebo. The majority 
of  patients  had  sporadic  disease  (90%),  metastatic 
stage (95%), and tumors that were positive for a RET 
mutation (56%). Patients were followed until disease 
progression, at which time they were unblinded and 
had the option to receive Vandetanib in an open-label 
trial; if they chose open-label Vandetanib, they were 
then followed for survival. The median duration of 
treatment was 90.1 weeks in the Vandetanib arm and 
39.9 weeks in the placebo arm. The primary objective 
of the ZETA study was demonstration of   improvement 
in progression-free survival (PFS) with   vandetanib 
compared to placebo. Other endpoints included eval-
uation of overall survival (OS) and objective response 
rate (ORR).
Two-year follow-up results showed that 37% of the 
patients had progression and 15% had died. The pri-
mary end point of the study, progression-free survival, 
was met with the researchers reporting a Hazard Ratio 
(HR) of 0.46 (95% Confidence Interval, 0.31–0.69). 
The median progression-free survival was 19.3 months 
in the placebo group and had not yet been reached in 
the Vandetanib arm at the time of the presentation at 
the  14th  International  Thyroid  Congress  in  2010. 
A significant improvement in PFS was observed for 
patients randomized to receive   vandetanib (HR = 0.35; 
95% CI: 0.24, 0.53; P , 0.0001).
While the PFS data led to US FDA approval, no 
significant OS difference was noted in the two arms 
because of the cross over design of the study.
Vandetanib  was  also  associated  with  statisti-
cally significant advantages in secondary endpoints 
such as objective response rate (45% vs. 13%; Odds   
Ratio (OR) = 5.4); disease control rate of 24 weeks 
or  more  (OR  =  2.64);  calcitonin  biochemical 
Table 1. Results of studies using vandetanib in the treat-
ment of MTC.
study Dose  
(mg)
Response  
rate
pFs  
months
Reference
08 300 20% 10.2 25
68 100 16% Not determined 26
58 300 45 Not reached 27Deshpande et al
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response  (OR  =  72.9);  CEA  biochemical  response 
(OR = 52); and time to worsening of pain (HR = 0.61). 
Some of the radiological responses were dramatic. At 
this time it is not known whether any   biochemical, 
radiological  or  clinical  parameters  significantly 
  predict for response. Similarly data is not yet avail-
able on whether certain metastatic sites respond   better 
than others. In the placebo arm, 12 of 13 responses 
occurred after the patients had received open-label 
Vandetanib. Adverse events were more common with 
Vandetanib  compared  to  placebo,  including  diar-
rhea  (56%  vs.  26%),  rash  (45%  vs.  11%),  nausea 
(33% vs. 16%), hypertension (32% vs. 5%) and head-
ache (26% vs. 9%). The most severe   toxicity was QT 
prolongation, torsades de pointes, and sudden death 
which are addressed in a boxed warning in the pre-
scribing information.
Based on these results, Astra Zeneca filed for Food 
and Drug Administration (FDA) approval of the drug 
in  the  United  States  and  the  European  Medicines 
Agency (EMEA) in Europe late in 2010, receiving an 
orphan drug designation by the FDA on   December 2, 
2010, with final approval granted on April 6 2011.27 
The approval was specifically for patients who are 
ineligible for surgery and have disease that is grow-
ing or causing symptoms. The benefits of the drug 
on patients who have occult or micrometastatic dis-
ease but with a rapid calcitonin doubling time are 
not known.
The severe cardiac side effects mentioned above 
are addressed in a boxed warning in the prescribing 
information. Vandetanib has a prolonged half-life of 
19 days, so ECGs and levels of serum potassium, cal-
cium, magnesium and TSH are recommended obtained 
at baseline, at 2–4 weeks and 8–12 weeks after start-
ing treatment and subsequently every 3 months.
As a result of the FDA concern about toxicity, only 
US prescribers and pharmacies certified through the 
Vandetanib  Risk  Evaluation  Mitigation  Strategy 
(REMS) Program, a restricted distribution program, 
are able to prescribe and dispense vandetanib.
Future possibilities for Vandetanib
The approval of Vandetanib as a systemic treatment 
for patients with unresectable or metastatic MTC was 
a landmark event and represents a new standard of 
care  for  these  patients.  However  further  improve-
ments  in  progression  free  and  overall  survival  are 
possible  and  may  be  achieved  with  combination 
  therapy using Vandetanib and either chemotherapy 
agents or other targeted treatments. The high cost of a 
new tyrosine kinase inhibitor is also likely to limit the 
number  of  patients  who  may  have  access  to  this 
medication.
Resistance may also arise in tumors exposed to 
Vandetanib. The authors speculate that there may be 
many reasons for this including new molecular abnor-
malities involving the RET or other receptors such as 
loss  of  expression,  genomic  amplification  or  the 
  activation  of  alternative  downstream  signaling 
  pathways. Further work needs to be done to elucidate 
which of these is most important. The combination of 
  Vandetanib  and  other  drugs  may  help  delay  or 
  overcome some resistance mechanisms.
Traditional chemotherapy
Chemotherapy agents including doxorubicin and cis-
platin have been evaluated in the treatment of MTC. 
While  the  medullary  subgroup  of  thyroid  cancers 
was thought to have the best response rates compared 
with differentiated and anaplastic types, no definitive 
studies have demonstrated a long term benefit. It has 
been suggested that responders to chemotherapy can 
see  an  improvement  in  overall  survival  from 
5–15 months, although randomized studies proving 
this have been lacking.28 Other agents such as pacli-
taxel  and  gemcitabine  that  have  broad  activity  in 
many cancers have been disappointing with regard to 
their effect on MTC.29
The authors have seen individual patients respond 
to  oral  chemotherapy  agents,  as  measured  by  bio-
chemical and radiological criteria (unpublished data); 
this is consistent with published reports showing pro-
gression free intervals of 11 months to four years in 
patients treated with the thymidylate synthetase inhib-
itor capecitabine.30 Further study should be done into 
newer  chemotherapy  agents  with  less  toxicity  and 
possibly in combination with targeted therapies such 
as Vandetanib.
Other ReT and veGFR inhibitors
Cabozantinib (XL-184)
Further investigation for a medicine with higher affinity 
for RET led to the development of another TKI inhibitor, 
XL-184 (cabozantinib), which also blocks VEGFR2 and 
c-MET. In a phase I trial including an expansion cohort vandetanib as a treatment for MTC
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of 23 subjects with MTC, almost all patients showed 
some degree of radiographic response, with 12 (55%) 
out of 22 evaluable patients achieving a partial response 
and 84% of patients achieving stable disease lasting for 
more than three months. The treatment was well toler-
ated, with the main side effects including diarrhea, nau-
sea, hypertension, and liver function test elevations at 
a dose of 175 mg daily. Long term follow up of these 
patients revealed a 41% partial response rate in a total of 
37 patients in whom the median progression free survival 
had not yet been reached.31 This promising new com-
pound is currently being evaluated in a phase III study 
in which patients with unresectable locally advanced, or 
metastatic MTC are randomized 2:1 to receive XL-184 
or placebo if they had demonstrated radiologically pro-
gressive disease prior to being enrolled.32
Motesanib
Motesanib (AMG-706), another multikinase inhibitor 
(VEGF/PDGF receptors, Kit and RET), was studied in 
a phase II trial of patients with advanced differentiated 
and  medullary  thyroid  cancer. All  patients  received 
Motesanib 125 mg daily until disease progression or 
unacceptable toxicity. The results for the MTC group 
(n = 91) after a median follow-up of 49 weeks showed 
a partial response rate of 2%, according to Response 
Evaluation Criteria In Solid Tumors (RECIST)   criteria. 
However, 81% had stable disease, which lasted more 
than 24 weeks in 48% of patients.33
Axitinib
Axitinib (AG-013736) is another oral small molecule 
inhibitor of tyrosine kinase that effectively inhibits the 
VEGF receptors but not RET.34 Nevertheless, patients 
with MTC were included in a multicenter, open-label 
phase II study looking at the use of axitinib in advanced 
or metastatic thyroid carcinoma. Axitinib was admin-
istered at a dose of 5 mg twice daily. Of the 60 patients 
who started therapy, the majority had differentiated 
thyroid cancer and 18% had MTC. The confirmed par-
tial response rate was 30% by intent-to-treat analysis 
(31% in differentiated thyroid cancer; 18% in MTC 
one patient with anaplastic thyroid cancer). Responses 
were  seen  in  patients  despite  previous  treatments 
with a variety of chemotherapeutic regimens. Median 
  progression-free survival was 18 months. Common 
adverse events included fatigue, stomatitis, proteinuria, 
diarrhea, hypertension and nausea.35
Sorafenib
Sorafenib  a  multikinase  inhibitor  targeting  RET 
and  VEGFR,  was  evaluated  in  a  phase  II  trial  in 
patients with advanced MTC, the primary end point 
of  which  was  objective  response.  Secondary  end 
points  included  toxicity  assessment  and  response 
correlation with tumor markers, functional imaging, 
and RET mutations. Using a two-stage design, 16 or   
25 patients were to be enrolled onto arms A (hereditary 
MTC) and B (sporadic MTC); all patients received 
sorafenib 400 mg orally twice daily. Only 5 patients 
were enrolled in arm A and it was therefore termi-
nated due to slow accrual. Of 16 patients treated in 
arm B, one achieved a partial response (6.3%; 95% 
CI, 0.2% to 30.2%), 14 had stable disease (87.5%; 
95% CI, 61.7% to 99.5%), and one was   nonevaluable. 
In a post hoc analysis of 10 arm B patients with pro-
gressive disease (PD) before study, one patient had a 
partial response of 21 months, four patients had stable 
disease for 15 months, four patients had stable dis-
ease for 6 months, and one patient had clinical pro-
gression of disease. Median progression-free survival 
was  17.9  months.  Common  adverse  events  (AEs) 
included diarrhea, hand-foot-skin reaction, rash, and 
  hypertension. Although serious adverse events were 
rare, one death was seen. Tumor markers decreased 
in the majority of patients, and RET mutations were 
detected in 10 of the 12 sporadic MTCs analyzed.36
Sunitinib
Sunitinib is a multitargeted tyrosine kinase inhibitor 
of VEGFR and RET making it a good candidate for a 
treatment of locally advanced and metastatic MTC. 
In a phase II study 35 patients with thyroid cancer, of 
whom had MTC, received 37.5 mg sunitinib daily 
until progression of disease or unresolved toxicities. 
The primary endpoint was overall response rate based 
on  RECIST  at  the  time  of  maximal  response. 
  Secondary endpoints included evaluation of time to 
tumor progression (TTP) overall survival (OS) and 
the safety and toxicity of this regimen. Three MTC 
patients had a partial response. The most common 
adverse  effects  were  fatigue,  diarrhea,  hand/foot 
  syndrome and neutropenia. Grade 3 toxicities included 
cytopenias (46%) diarrhea (17%), hand/foot   syndrome 
(17%) and fatigue (11%). The median survival in this 
study had not been reached at the time of   publication 
of study results.37Deshpande et al
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Phase III studies
To date there have been no Phase III studies using 
Vandetanib in MTC treatment although the random-
ized  Phase  II  fulfilled  the  need  for  a  comparison 
against a placebo arm. Further Phase III trials using 
this agent will likely be in the form of combination 
therapy compared to monotherapy, or a comparison 
of Vandetanib with one of the other small molecule 
inhibitors listed above.
Summary
Vandetanib has emerged as an effective targeted ther-
apy in the treatment of MTC. Its recent FDA approval 
for patients with metastatic or unresectable disease is 
a landmark in the history of this condition. Its devel-
opment as a targeted agent and the results of phase II 
and  randomized  studies  have  become  a  proof  of 
  principal. Future studies involving combinations with 
other systemic agents are eagerly awaited and may 
further improve upon the significant results seen to 
date with this agent.
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